Table 2.
Zone of clearance (mm) and phenotypic resistance determination for clinical Pseudomonas aeruginosa isolates.
| Pa-3 | Pa-8 | ATCC 27853 | |||
|---|---|---|---|---|---|
| Antibiotic | Kirby–Bauer (mm) | Interpretation | Kirby–Bauer (mm) | Interpretation | Kirby–Bauer (mm) |
| Delafloxacin | 6 | Resistant | 6 | Resistant | 23–29 |
| Ceftazidime | 6 | Resistant | 6 | Resistant | 22–29 |
| Cefepime | 6 | Resistant | 6 | Resistant | 25–31 |
| Meropenem | 6 | Resistant | 6 | Resistant | 27–33 |
| Imipenem | 6 | Resistant | 25 | Sensitive | 20–28 |
| Piperacillin/tazobactam | 24 | Sensitive | 19 | Intermediate | 25–33 |
| Ceftolozane/tazobactam | 6 | Resistant | 29 | Sensitive | 25–31 |
| Ceftazidime/avibactam | 6 | Resistant | 26 | Sensitive | 25–31 |
| Ciprofloxacin | 6 | Resistant | 6 | Resistant | 25–33 |
| Levofloxacin | 6 | Resistant | 6 | Resistant | 19–26 |
| Gentamicin | 6 | Resistant | 6 | Resistant | 17–23 |
| Amikacin | 6 | Resistant | 17 | Sensitive | 18–26 |
| Trimethoprim/sulfamethoxazole | 6 | NA | 6 | NA | — |
| Fosfomicin | 12 | Resistant | 15 | Intermediate | — |
| Colistin | 13 | Sensitive | 15 | Sensitive | 11–17 |
| Aztreonam | 17 | Intermediate | 16 | Intermediate | 23–29 |
| Doxycycline | 6 | NA | 6 | NA | — |
| Minocycline | 6 | NA | 6 | NA | — |
| Tigecycline | 6 | NA | 6 | NA | 9–13 |
| Nitrofurantoin | 6 | NA | 6 | NA | — |
| Carbapenem inactivation assay | 14 | Positive | 27 | Positive | — |
NA indicates that no interpretive criteria have been established. ATCC 27853 values are disk diffusion QC ranges provided by the CLSI63.